CAS 1325223-34-4

Pelitinib-d6

Produit contrôlé

CAS : 1325223-34-4

Applications Labelled Pelitinib (P218702). A tyrosine kinase inhibitor; it is used to prepare formulation for treating primary or secondary cancer.
References Veronese, M., et al.: Br. J. Cancer, 92, 1846 (2005), Hofheinz, R., et al.: Onkologie, 29, 563 (2006), Meyerhardt, J., et al.: J. Clin. Oncol., 24, 1892 (2006), Hanauske, A., et al.: Clin. Cancer Res., 13, 523 (2007),

Formule : C₂₄H₁₇D₆ClFN₅O₂

Couleur et forme : Neat

Masse moléculaire : 473.96

Ref: TR-P218702

Pelitinib-d6

CAS : 1325223-34-4

Pelitinib-d6 is an anticancer drug that inhibits the activity of protein kinases, which are enzymes involved in cell cycle regulation and apoptosis. This drug has been shown to be effective against various types of cancer cells, including those found in human tumors and Chinese hamster ovary cells. Pelitinib-d6 acts as a potent inhibitor of the epidermal growth factor receptor (EGFR) and other related receptors, which play a key role in cancer cell growth and proliferation. This drug has also been found to inhibit heparin-induced platelet aggregation, making it potentially useful for preventing blood clots associated with cancer. Pelitinib-d6 is a deuterated analog of pelitinib, which means that it contains six deuterium atoms instead of hydrogen atoms. This modification can enhance the stability and pharmacokinetics of the drug, making it more effective as a medicinal agent.

Formule : C₂₄H₂₃ClFN₅O₂

Degré de pureté : Min. 95%

Masse moléculaire : 474 g/mol

Ref: 3D-ADC22334